• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

揭示EPH/ Ephrin信号通路在肝癌中的意义:对肿瘤进展及治疗意义的见解

Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications.

作者信息

Papadakos Stavros P, Stergiou Ioanna E, Gkolemi Nikolina, Arvanitakis Konstantinos, Theocharis Stamatios

机构信息

First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

出版信息

Cancers (Basel). 2023 Jun 30;15(13):3434. doi: 10.3390/cancers15133434.

DOI:10.3390/cancers15133434
PMID:37444544
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10340246/
Abstract

Liver cancer is a complex and challenging disease with limited treatment options and dismal prognosis. Understanding the underlying molecular mechanisms driving liver cancer progression and metastasis is crucial for developing effective therapeutic strategies. The EPH/ephrin system, which comprises a family of cell surface receptors and their corresponding ligands, has been implicated in the pathogenesis of HCC. This review paper aims to provide an overview of the current understanding of the role of the EPH/ephrin system in HCC. Specifically, we discuss the dysregulation of EPH/ephrin signaling in HCC and its impact on various cellular processes, including cell proliferation, migration, and invasion. Overall, the EPH/ephrin signaling system emerges as a compelling and multifaceted player in liver cancer biology. Elucidating its precise mechanisms and understanding its implications in disease progression and therapeutic responses may pave the way for novel targeted therapies and personalized treatment approaches for liver cancer patients. Further research is warranted to unravel the full potential of the EPH/ephrin system in liver cancer and its clinical translation.

摘要

肝癌是一种复杂且具有挑战性的疾病,治疗选择有限,预后不佳。了解驱动肝癌进展和转移的潜在分子机制对于制定有效的治疗策略至关重要。EPH/ephrin系统由一类细胞表面受体及其相应配体组成,已被认为与肝癌的发病机制有关。这篇综述旨在概述目前对EPH/ephrin系统在肝癌中作用的理解。具体而言,我们讨论了肝癌中EPH/ephrin信号传导的失调及其对各种细胞过程的影响,包括细胞增殖、迁移和侵袭。总体而言,EPH/ephrin信号系统在肝癌生物学中是一个引人注目的多面角色。阐明其精确机制并了解其在疾病进展和治疗反应中的意义,可能为肝癌患者的新型靶向治疗和个性化治疗方法铺平道路。有必要进一步研究以揭示EPH/ephrin系统在肝癌中的全部潜力及其临床转化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88cb/10340246/59cbf55f136e/cancers-15-03434-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88cb/10340246/b15ec5cbced1/cancers-15-03434-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88cb/10340246/d4aa1ea2a901/cancers-15-03434-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88cb/10340246/59cbf55f136e/cancers-15-03434-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88cb/10340246/b15ec5cbced1/cancers-15-03434-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88cb/10340246/d4aa1ea2a901/cancers-15-03434-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88cb/10340246/59cbf55f136e/cancers-15-03434-g003.jpg

相似文献

1
Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications.揭示EPH/ Ephrin信号通路在肝癌中的意义:对肿瘤进展及治疗意义的见解
Cancers (Basel). 2023 Jun 30;15(13):3434. doi: 10.3390/cancers15133434.
2
The Functions of EphA1 Receptor Tyrosine Kinase in Several Tumors.EphA1 受体酪氨酸激酶在几种肿瘤中的功能。
Curr Med Chem. 2023;30(20):2340-2353. doi: 10.2174/0929867329666220820125638.
3
The role of Eph receptors and ephrin ligands in colorectal cancer.Eph 受体和 Ephrin 配体在结直肠癌中的作用。
Int J Cancer. 2010 May 1;126(9):2003-11. doi: 10.1002/ijc.25147.
4
Emerging Roles for Eph Receptors and Ephrin Ligands in Immunity.Eph 受体和 Ephrin 配体在免疫中的新兴作用。
Front Immunol. 2019 Jul 4;10:1473. doi: 10.3389/fimmu.2019.01473. eCollection 2019.
5
The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment.EPH/Ephrin 系统在胰腺导管腺癌(PDAC)中的作用:从发病机制到治疗。
Int J Mol Sci. 2023 Feb 3;24(3):3015. doi: 10.3390/ijms24033015.
6
Ephrin or not? Six tough questions on Eph targeting.有 Ephrin 还是没有?Eph 靶向的六个难题
Expert Opin Ther Targets. 2020 May;24(5):403-415. doi: 10.1080/14728222.2020.1745187. Epub 2020 Mar 26.
7
A review on Eph/ephrin, angiogenesis and lymphangiogenesis in gastric, colorectal and pancreatic cancers.关于Eph/ephrin、血管生成和淋巴管生成在胃癌、结直肠癌和胰腺癌中的综述
Chin J Cancer Res. 2017 Aug;29(4):303-312. doi: 10.21147/j.issn.1000-9604.2017.04.03.
8
Eph/Ephrin Signaling in the Tumor Microenvironment.肿瘤微环境中的 Eph/Ephrin 信号通路。
Adv Exp Med Biol. 2021;1270:45-56. doi: 10.1007/978-3-030-47189-7_3.
9
The EPH/Ephrin System in Bone and Soft Tissue Sarcomas' Pathogenesis and Therapy: New Advancements and a Literature Review.EPH/Ephrin 系统在骨与软组织肉瘤发病机制和治疗中的作用:新进展和文献回顾。
Int J Mol Sci. 2022 May 5;23(9):5171. doi: 10.3390/ijms23095171.
10
Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma.Ephrin-A3/EphA2 轴调节细胞代谢可塑性,增强低氧肝癌中的癌症干性。
J Hepatol. 2022 Aug;77(2):383-396. doi: 10.1016/j.jhep.2022.02.018. Epub 2022 Feb 25.

引用本文的文献

1
Single-Gene Mutations in Hepatocellular Carcinoma: Applications and Challenges in Precision Medicine.肝细胞癌中的单基因变异:精准医学中的应用与挑战
Int J Med Sci. 2025 Jul 10;22(13):3268-3276. doi: 10.7150/ijms.117603. eCollection 2025.
2
Advances and current concepts on Eph receptors and ephrins in upper digestive tract cancers.上消化道癌症中Eph受体和ephrin的研究进展与当前概念
Front Oncol. 2025 Jan 7;14:1520306. doi: 10.3389/fonc.2024.1520306. eCollection 2024.
3
Upregulation of Differentiates Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma and Both Colorectal and Pancreatic Adenocarcinoma Liver Metastases.

本文引用的文献

1
Cholangiocarcinoma in the Era of Immunotherapy.免疫治疗时代的胆管癌
Vaccines (Basel). 2023 Jun 5;11(6):1062. doi: 10.3390/vaccines11061062.
2
The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?二甲双胍在肝细胞癌治疗中的新作用:将二甲双胍重新用于肝癌免疫治疗有价值吗?
Cancers (Basel). 2023 Jun 13;15(12):3161. doi: 10.3390/cancers15123161.
3
The Role of TLR4 in the Immunotherapy of Hepatocellular Carcinoma: Can We Teach an Old Dog New Tricks?
的上调可区分肝内胆管癌与肝细胞癌以及结直肠癌和胰腺癌肝转移。 (注:原文句子不完整,“Upregulation of”后面缺少具体内容)
Genes (Basel). 2024 Nov 28;15(12):1545. doi: 10.3390/genes15121545.
4
DNA methylation biomarker panels for differentiating various liver adenocarcinomas, including hepatocellular carcinoma, cholangiocarcinoma, colorectal liver metastases and pancreatic adenocarcinoma liver metastases.用于区分各种肝腺癌的 DNA 甲基化生物标志物面板,包括肝细胞癌、胆管癌、结直肠癌肝转移和胰腺腺癌肝转移。
Clin Epigenetics. 2024 Nov 4;16(1):153. doi: 10.1186/s13148-024-01766-z.
5
The Clinical Relevance of the EPH/Ephrin Signaling Pathway in Pediatric Solid and Hematologic Malignancies.EPH/Ephrin 信号通路在儿科实体和血液恶性肿瘤中的临床意义。
Int J Mol Sci. 2024 Mar 29;25(7):3834. doi: 10.3390/ijms25073834.
6
Interplay of Extracellular Vesicles and TLR4 Signaling in Hepatocellular Carcinoma Pathophysiology and Therapeutics.细胞外囊泡与TLR4信号通路在肝细胞癌病理生理学及治疗中的相互作用
Pharmaceutics. 2023 Oct 13;15(10):2460. doi: 10.3390/pharmaceutics15102460.
7
Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches.肥胖与肝癌发生的十字路口会议:独特的病理生理途径为创新治疗方法带来期望。
Int J Mol Sci. 2023 Sep 28;24(19):14704. doi: 10.3390/ijms241914704.
8
Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation.揭示肝癌中 M1 和 M2 巨噬细胞的阴阳平衡:外泌体在肿瘤微环境和免疫调节中的作用。
Cells. 2023 Aug 10;12(16):2036. doi: 10.3390/cells12162036.
Toll样受体4在肝细胞癌免疫治疗中的作用:我们能让老狗学新把戏吗?
Cancers (Basel). 2023 May 17;15(10):2795. doi: 10.3390/cancers15102795.
4
Diagnosis and Management of Cirrhosis and Its Complications: A Review.肝硬化及其并发症的诊断与管理:综述。
JAMA. 2023 May 9;329(18):1589-1602. doi: 10.1001/jama.2023.5997.
5
Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.非酒精性脂肪性肝病与肝细胞癌:流行病学、发病机制、影像学、预防和治疗的新视角。
Semin Cancer Biol. 2023 Aug;93:20-35. doi: 10.1016/j.semcancer.2023.04.010. Epub 2023 May 4.
6
Pathological angiogenesis: mechanisms and therapeutic strategies.病理性血管生成:机制与治疗策略。
Angiogenesis. 2023 Aug;26(3):313-347. doi: 10.1007/s10456-023-09876-7. Epub 2023 Apr 15.
7
Combination immunotherapy for hepatocellular carcinoma.肝细胞癌的联合免疫治疗。
J Hepatol. 2023 Aug;79(2):506-515. doi: 10.1016/j.jhep.2023.03.003. Epub 2023 Mar 16.
8
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?胆管癌靶向治疗格局的演变:胆管癌是胃肠道肿瘤学中的“非小细胞肺癌”吗?
Cancers (Basel). 2023 Mar 3;15(5):1578. doi: 10.3390/cancers15051578.
9
Neddylation of EphB1 Regulates Its Activity and Associates with Liver Fibrosis.EphB1 的泛素化调节其活性,并与肝纤维化相关。
Int J Mol Sci. 2023 Feb 8;24(4):3415. doi: 10.3390/ijms24043415.
10
Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview.失代偿期肝硬化患者肝细胞癌的管理:全面概述
Cancers (Basel). 2023 Feb 18;15(4):1310. doi: 10.3390/cancers15041310.